10 results
- Can early Botox-injections in the bladder of patients with meningomyelocèle (MMC) prevent deterioration of the bladder and renal function?- Can early Botox-injections in the bladder of patients with meningomyelocèle (MMC) decrease the need for an…
This study will evaluate the effect of approximately 10 years of pravastatin treatment on IMT in young adults with FH. Furthermore, safety parameters and psychological aspects with respect to early treatment initiation will be investigated.
Riskreduction of developing breast carcinoma by means of better surgical techniques (removing all normal breast tissue).
The study aims at examining the effect of an individual tailored lifestyle intervention to reduce the cardiovascular disease risk in people with FH.Secundary, the study aims at promoting a healthy lifestyle (no smoking, proper nutritional pattern,…
The objective of this research is to develop a method which can identify among all consanguineous couples the ones which are at high risk.
The aim of this study is to evaluate the efficacy, safety, compliance and tolerability of 15 years of pravastatin therapy initiated during childhood in young adult FH patients.
This study has been transitioned to CTIS with ID 2023-504593-38-00 check the CTIS register for the current data. The aim of this trial is to infuse multiple doses of human 1st trimester liver-derived MSC for the treatment of severe OI to determine…
To evaluate RRS after childbearing with delayed RRO as an alternative for RRSO in BRCA1/2 gene germline mutation carriers. We hypothesize that delay of menopause leads to an improvement of quality of life and sexual functioning, and a decrease in…
To identify arrhythmogenic electromechanical risk profiles in LQTS patients; in baseline conditions and during provocation; the recognition of risk profiles will improve risk stratification for sudden cardiac death.
To evaluate RRS with delayed RRO as an alternative for RRSO in BRCA1/2 gene germline mutation carriers. We hypothesize that RRS with delayed RRO leads to an equal ovarian cancer incidence when compared to RRSO.